Notice: This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:IMMVF Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisShort Interest About Immunovia AB (publ) Stock (OTCMKTS:IMMVF) 30 days 90 days 365 days Advanced Chart Remove Ads Get Immunovia AB (publ) alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range N/A52-Week Range$0.84▼$2.00VolumeN/AAverage Volume12,942 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImmunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.Read More… Remove Ads Receive IMMVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovia AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMVF Stock News HeadlinesQ4 2024 Immunovia AB (publ) Earnings Call TranscriptFebruary 26, 2025 | gurufocus.comQ3 2024 Immunovia AB (publ) Earnings Call TranscriptDecember 2, 2024 | gurufocus.comTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…March 12, 2025 | Porter & Company (Ad)Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortiumNovember 7, 2024 | prnewswire.comImmunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conferenceSeptember 16, 2024 | prnewswire.comImmunovia publishes prospectus relating to the rights issueMarch 17, 2023 | prnewswire.comImmunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d testDecember 5, 2022 | finance.yahoo.comCenters for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia's IMMray PanCan-d testNovember 30, 2022 | finance.yahoo.comSee More Headlines IMMVF Stock Analysis - Frequently Asked Questions How were Immunovia AB (publ)'s earnings last quarter? Immunovia AB (publ) (OTCMKTS:IMMVF) posted its quarterly earnings data on Friday, November, 29th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Company Calendar Last Earnings11/29/2013Today3/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IMMVF CIKN/A Webwww.imvaccine.com Phone(902) 492-1819FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:IMMVF) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovia AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovia AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.